Full-Time

General Manager

Hope Lodge

Posted on 4/7/2025

American Cancer Society

American Cancer Society

5,001-10,000 employees

Advocacy, research, and patient support for cancer

No salary listed

Mid, Senior

Nashville, TN, USA

Category
Generalist Operations
Supply Chain Management
Operations & Logistics
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a American Cancer Society referral from your network.

đź’ˇ

Applications through a referral are 3x more likely to get an interview!

Requirements
  • 3-5 Years Experience in nonprofit management, healthcare administration, hospitality management, or a related field (bachelor's degree preferred)
  • Proven leadership experience in a nonprofit, healthcare, or hospitality setting, with a track record of success in strategic execution, team management, and operational excellence
  • Strong communication, interpersonal, and organizational skills, with the ability to build and maintain relationships with diverse stakeholders
  • Compassionate and empathetic approach to serving cancer patients and their caregivers, with a commitment to delivering exceptional guest experiences
  • Ability to thrive in a dynamic and fast-paced environment, with a strategic mindset and a passion for making a difference in the lives of others
Responsibilities
  • Drive the implementation of strategic initiatives aimed at optimizing the operation and impact of the Hope Lodge, in alignment with ACS goals and objectives
  • Enhance brand visibility and recognition for the Hope Lodge within the community and among relevant stakeholders, promoting its mission and services
  • Forge collaborative partnerships with health systems, healthcare providers, donors, volunteers and other ACS departments to expand resources, support services, and outreach efforts for lodge guests
  • Provide comprehensive oversight of all aspects of Hope Lodge operations, including guest services, facility maintenance, staff management, and adherence to ACS standards, ensuring excellence in service delivery
  • Prioritize the provision of exceptional hospitality, support services, and accommodations to cancer patients and their caregivers, fostering a compassionate and supportive environment and maintaining High Guest Satisfaction
  • Responsible for leading a high-performing team, and developing team culture. Responsible to recruit, train, and lead a dedicated team of managers, cultivating a culture of excellence, teamwork, and compassion in serving lodge guests
  • Engage with local communities, civic organizations, and volunteers to build support networks, raise awareness, and facilitate fundraising initiatives in support of lodge operations
  • Manage budgets, monitor financial performance, and implement cost-effective strategies to ensure the sustainability and growth of Hope Lodge operations. Responsible to support development fundraising efforts
Desired Qualifications
  • Leadership: Ability to provide strong leadership and direction to staff and volunteers, fostering a positive and collaborative work environment
  • Strategic Thinking: Capacity to develop and execute strategic plans to achieve organizational goals and enhance the impact of the Hope Lodge within the community
  • Operational Management: Proficiency in overseeing all aspects of lodge operations, including guest services, facility maintenance, and adherence to ACS standards
  • Brand Management: Skill in enhancing brand visibility and recognition for the Hope Lodge, promoting its mission and services effectively
  • Partnership Development: Ability to forge and maintain partnerships with health systems, healthcare providers, donors, volunteers and other ACS departments to expand resources and support services for lodge guests
  • Guest Experience: Dedication to providing exceptional hospitality, support services, and accommodations to cancer patients and their caregivers, ensuring their comfort and well-being during their treatment journeys
  • Financial Management: Experience in developing and managing budgets, monitoring financial performance, and implementing cost-effective strategies to ensure the sustainability of lodge operations
  • Communication: Excellent verbal and written communication skills, with the ability to effectively interact with diverse stakeholders including guests, staff, volunteers, and community partners
  • Interpersonal Skills: Strong interpersonal skills, including empathy, compassion, and the ability to build and maintain positive relationships with individuals experiencing challenging circumstances
  • Problem-Solving: Capacity to identify issues, develop creative solutions, and make timely and sound decisions to address operational challenges and guest needs
  • Organizational Skills: Strong organizational skills, with the ability to prioritize tasks, manage multiple projects simultaneously, and meet deadlines in a fast-paced environment
  • Team Building: Skill in recruiting, training, and leading a diverse team of staff and volunteers, fostering a culture of excellence, teamwork, and compassion
  • Adaptability: Flexibility and adaptability to navigate changing priorities, unexpected events, and evolving needs of guests and stakeholders
  • Commitment to Mission: Dedication to the mission of the American Cancer Society and a passion for making a meaningful impact on the lives of cancer patients and their caregivers
American Cancer Society

American Cancer Society

View

The American Cancer Society focuses on fighting cancer and improving the lives of those affected by it. They provide support through advocacy, research, and patient assistance, ensuring that individuals have access to prevention, detection, treatment, and survivorship resources. Their approach is unique because they combine these elements to create a comprehensive support system for patients and their families. The goal of the American Cancer Society is to end cancer for everyone, making sure that no one faces cancer alone.

Company Size

5,001-10,000

Company Stage

Series B

Total Funding

$2.7M

Headquarters

Atlanta, Georgia

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • AI in cancer diagnosis improves patient outcomes and reduces healthcare costs.
  • Telemedicine and remote monitoring enhance cancer care accessibility and patient health tracking.
  • New immunotherapies in trials show promise for effective cancer treatments.

What critics are saying

  • Competition from AstraZeneca's Calquence in CLL treatment challenges traditional methods.
  • New diagnostic technologies like Blue Light Cystoscopy may shift focus from traditional research.
  • ACS's gaming partnership with Besitos may divert resources from traditional campaigns.

What makes American Cancer Society unique

  • ACS partners with Besitos to merge gaming with philanthropy for cancer awareness.
  • ACS funds MSU research in colorectal, breast, and cervical cancer with $3 million grants.
  • ACS's Trailblazers in Cancer Executive Leadership Committee includes top medical professionals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Paid Vacation

401(k) Retirement Plan

Wellness Program

Professional Development Budget

Company News

PharmiWeb
Apr 30th, 2025
Fixed-Duration Calquence-Based Regimens Recommended For Approval In The Eu By Chmp For 1St-Line Chronic Lymphocytic Leukaemia

Recommendation based on AMPLIFY Phase III trial which showed Calquencecombinations demonstrated statistically significant and clinically meaningfulimprovement in progression-free survival vs. chemoimmunotherapyA fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the AMPLIFY Phase III trial, which were presented at the American Society of Haematology (ASH) 2024 Annual Meeting and published in The New England Journal of Medicine.1Results showed Calquence plus venetoclax reduced the risk of disease progression or death by 35% compared to standard-of-care chemoimmunotherapy (investigator’s choice of fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab; hazard ratio [HR] 0.65; 95% confidence interval [CI] 0.49-0.87; p=0.0038). Calquence plus venetoclax with obinutuzumab demonstrated a 58% reduction in the risk of disease progression or death compared to standard-of-care chemoimmunotherapy (HR 0.42; 95% CI 0.30-0.59; p<0.0001).2At three years, 77% of patients treated with Calquence plus venetoclax and 83% of patients treated with Calquence plus venetoclax and obinutuzumab were progression free, versus 67% of patients treated with chemoimmunotherapy.1 Median progression-free survival (PFS) was not reached for either experimental arm versus 47.6 months for chemoimmunotherapy.1Wojciech Jurczak, MD, Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland and investigator for the trial, said: “Chronic lymphocytic leukaemia is an incurable cancer which means patients live with the disease and stay on treatment for many years, which can have long-term effects. The fixed-duration Calquence regimens will allow patients to take breaks from their treatment, reducing the risk of long-term adverse events and drug resistance.”Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “With this recommendation, Calquence plus venetoclax can potentially be the only all-oral second-generation BTK inhibitor option approved in Europe for patients with previously untreated chronic lymphocytic leukaemia. Calquence has demonstrated efficacy and safety in fixed-duration and treat-to-progression regimens providing patients and their doctors more treatment flexibility.”CLL is the most common type of leukaemia in adults, with an estimated 27,000 patients diagnosed in the UK, France, Germany, Spain and Italy in 2024.3The safety and tolerability of Calquence was consistent with its known safety profile, and no new safety signals were identified.Regulatory applications for Calquence plus venetoclax, with or without obinutuzumab, in this setting are currently under review in several countries based on the AMPLIFY results.NotesChronic lymphocytic leukaemia (CLL)CLL is the most prevalent type of leukaemia in adults, with over 117,000 new cases globally in 2021.4 Although some people with CLL may not experience any symptoms at diagnosis, others may experience symptoms, such as weakness, fatigue, weight loss, chills, fever, night sweats, swollen lymph nodes and abdominal pain.5 In CLL, there is an accumulation of abnormal lymphocytes within the blood, bone marrow and lymph nodes. As the number of abnormal cells increases, there is less room within the marrow for the production of normal white blood cells, red blood cells and platelets.6 This could result in infection, anaemia and bleeding

PR Newswire
Apr 29th, 2025
Bladder Cancer Presentations At Aua2025: Blue Light Cystoscopy Improves Risk Stratification And Informed Decision Making

OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk stratification and therefore the ability of the BLC procedure to help urologists and patients make well-informed decisions. The American Urological Association Annual Congress 2025 was held April 26-28, at the Venetian Convention & Expo Center in Las Vegas, NV, USA.Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure in 2014 and projected to enroll 4,400 patients. In addition, the study protocol of a randomized controlled non-inferiority trial comparing a multidisciplinary approach including PDD-guided primary TURBT to reduce the patients' burden of second resection including a total of 327 patients has been presented. This investigator-initiated trial is supported by Photocure.The abstract sessions on Saturday, April 26:"Upstaging and Risk Migration with BLC for NMIBC: Results from a prospective multicenter registry" by Alireza Ghoreifi, Duke UniversityThe study looked at 2,854 NMIBC* patients from the US Blue Light Cystoscopy with Cysview Registry. A total of 201 (7%) patients had at least one malignant lesion detected exclusively by BLC while having a negative WLC

Cision
Apr 29th, 2025
Fixed-Duration Calquence Recommended In Eu For Cll

Fixed-duration Calquence recommended in EU for CLL

South Florida Hospital News
Apr 28th, 2025
American Cancer Society and Besitos Join Forces to Fight Cancer Through Mobile Gaming

Tampa, FL - April 28, 2025 - The American Cancer Society (ACS) has announced an innovative partnership with Besitos, a leading gaming company, to merge entertainment with philanthropy.

PharmiWeb
Apr 24th, 2025
Hutchmed Highlights Data To Be Presented At Aacr Annual Meeting 2025

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

INACTIVE